The following is a summary of “Significance of serum sestrin2 as a biomarker of severity and functional outcome in acute intracerebral hemorrhage: a prospective observational longitudinal study,” published in the November 2023 issue of Neurology by Dou et al.

Researchers examined whether serum sestrin2 levels could predict patient outcomes in intracerebral hemorrhage (ICH) cases.

They recruited 126 patients with supratentorial ICH as cases and 126 healthy individuals as controls. Severity was evaluated using the National Institutes of Health Stroke Scale (NIHSS) and hematoma volume. Prognostic parameters included early neurologic deterioration (END) and a 6-month poor prognosis post-stroke (modified Rankin Scale (mRS) scores of 3–6). Multivariate analysis examined the associations between serum sestrin2 levels and severity and prognosis.

The results showed patients exhibited significantly higher serum sestrin2 levels compared to controls. These levels correlated independently with NIHSS scores and hematoma volume. Additionally, increased proportionally with mRS scores from 0 to 6. Serum sestrin2 emerged as an independent predictor for both END and poor prognosis. In predictive ability, serum sestrin2 performed similarly to NIHSS scores and hematoma volume based on the receiver operating characteristic curve. Integration of serum sestrin2, NIHSS scores, and hematoma volume in prediction models for END and poor prognosis, visualized through nomograms, demonstrated reliability and stability, with clinical benefits confirmed by decision curve analysis. Notably, the prediction model for poor prognosis outperformed individual predictors (NIHSS scores, hematoma volume, and serum sestrin2) in discriminatory efficiency.

They concluded that Elevated serum sestrin2 levels independently predicted worse outcomes in acute ICH patients.

Source: bmcneurol.biomedcentral.com/articles/10.1186/s12883-023-03470-6